Navigation Links
Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution

Tecan Group and Luminex Corporation Partner to Develop Automated Newborn... -- MANNEDORF, Switzerland and AUSTIN, Texas, Oct. 12 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Joint Ventures, Children-related News Click to view news release full screen  

Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution


New solution combines multiplexing and automation technologies to create novel system that provides faster results and saves valuable time and resources in newborn screening laboratories

Download image

Download image

MANNEDORF, Switzerland and AUSTIN, Texas, Oct. 12 /PRNewswire-FirstCall/ -- The Tecan Group (SIX Swiss Exchange: TECN) and Luminex Corporation (Nasdaq: LMNX) have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns.  The companies have entered into a global OEM agreement that allows them to combine Luminex® xMAP® technology and LX 200™ instrument with Tecan's flexible and reliable Freedom EVO® liquid handling platform and HydroFlex™ washer.  The new automated newborn screening solution will help laboratories enhance efficiency, save vital resources and analyze more samples more quickly.  Luminex expects to launch the automated newborn screening solution in 2011.



Thomas Bachmann, CEO of Tecan, said: "We are delighted that we have been chosen by Luminex to supply a fully automated solution for such an important application. This global OEM agreement is building on a long, well established partnership of creating the most advanced automated solutions in the research market for Luminex xMAP technology."

Luminex xMAP technology enables large numbers of biological tests to be conducted simultaneously and analyzed quickly, cost-effectively and accurately. Once it receives regulatory clearance, NeoPlex4™ will be a fully automated, walk-away testing platform for multiplexed newborn screening.  These high-volume screening assays test newborn infants for several different biomarkers linked to critical diseases.  Each of these conditions can cause severe mental and physical disability if untreated.  If detected early through testing, effective treatment can be initiated.  Multiplexing these tests together from one sample offers significant improvements in testing efficiency.

Patrick Balthrop, CEO of Luminex, said: "Automation continues to be a top priority for Luminex and our customers.  The high testing volumes in the newborn screening market require full sample-to-answer automation for the thousands of specimens processed by each customer per day.  We evaluated several different robotic solutions to achieve this full automation for our xMAP technology and determined that Tecan was the best option available for this application.  We have had a very effective relationship with Tecan and we are proud to be partnered with them in this effort."

About TecanTecan ( is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at further information:Tecan GroupMartin BraendleHead of Corporate Communications & Investor RelationsTel. +41 (0) 44 922 84 30Fax +41 (0) 44 922 88 89investor@tecan.comwww.tecan.comLuminex Contacts:Luminex Corporate Contact:Harriss T. Currie, Vice President, Finance and Chief Financial Officer512.219.8020Matthew ScaloSr. Director Investor Relations512.219.8020mscalo@luminexcorp.comLuminex Media Contact:Aaron

SOURCE Luminex Corporation; The Tecan Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
3. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
4. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. NEXUS Biosystems Acquires Tecan Groups REMP Sample Management Business
8. NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group
9. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
Post Your Comments:
(Date:10/9/2015)... -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today announced ... Society of Emergency Medicine (EuSEM) meeting to be held October ... the Lingotto Congress Centre in Turin, Italy ... medicine practitioners in the world with over 2000 delegates in ... previously announced phase 2 bunionectomy trial will also be included.  ...
(Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. ... focused on gastrointestinal and cardio-renal diseases, today announced ... candidate, tenapanor, will be presented at the 2015 ... findings will include measures of sustained response in ... blind, placebo-controlled, randomized Phase 2 trial. The meeting ...
Breaking Medicine Technology:
... ,, NEW YORK , Aug. 3 ITelagen, a ... it was selected by Manhattan ,s Physician Group (MPG) to host, ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... for staff members. , , ...
... PHILADELPHIA , Aug. 3 ... a safe, isotope-free alternative to traditional radiation therapy ... focus of 14 clinical research studies presented at ... Meeting.  According to Xoft, Inc., the clinical benefits ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation (AOF) ... Medical Education J. Michael Finley, DO, as the recipient of the 2015 W. ... impact on graduate medical education opportunities for osteopathic residents, and his dedication to ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... For ... breast cancer victims, survivors, and the ongoing effort to find a cure. At Beverly ... outlet for helping women in need. With their Bra Collection Campaign, Beverly Hills Physicians ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... A new ... Home Exam Aid, is now available online ( ) – just in time ... (CDC) says officially begins in October. However, for many in the U.S., the real ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save ... can cut the risk of dying in reported home fires in half. As part ... sure smoke alarms are property installed and maintained. , Half of home fire deaths ...
Breaking Medicine News(10 mins):
... Mass., April 22 Haemonetics Corporation announced today that it will host its ... 12:30 pm at its corporate headquarters in Braintree, Massachusetts.The agenda for the meeting ... 2010 Annual Operating Plan Review , Plasma ... , R&D Progress , , ...
... combination of herbal ingredients contained in the anti-oxidant LiverLife ... reduce allergic responses in children with Autism Spectrum Disorder.LAGUNA ... brunt of the chemical age, accumulating toxins that weaken ... LiverLife(TM) significantly lowers the immune response ...
... It,s not every day people have the opportunity to ... From April 1 through June 30, 2009, however, The ICEcard ... do just that.A durable plastic card the size of a ... ICEcard, lists a person,s full name, age, address and phone ...
... Community, Overcharging Employers and Driving Up Healthcare ... Health System (WPAHS) yesterday filed a complaint in ... hospital system, and Highmark, Inc., Pittsburgh,s dominant health ... to protect one another from competition," with the ...
... Highlight Data for its Two Newest Urological Products -CORONA, ... WPI ), a global leader in the development ... host and webcast a meeting for the investment community ... place in Chicago, Illinois, April 25-30, 2009. The company ...
... The American Society of Hypertension, Inc. (ASH) today ... hypertension and related cardiovascular disease -- the ASH Hypertension ... of allied health professionals and pharmaceutical sales representatives. While ... the educational needs of each of the intended target ...
Cached Medicine News:
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
... RNA, Or Fluorescent Tags. Accurate quantitation of minute ... life science research. The RF-Mini 150 Fluorometer offers ... small as 1ng/ml of DNA specific Hoechst Dye. ... emission filters, the RF-Mini 150 can measure RNA ...
Medicine Products: